Luzia Hermínia Sousa1, Eveline V M Linhares1, Joanna Trycia Alexandre2, Mario Roberto Lisboa3, Flávia Furlaneto4, Raul Freitas3, Isabela Ribeiro5, Danielle Val6, Mirna Marques1,7, Hellíada Vasconcelos Chaves1,2, Conceição Martins3, Gerly A C Brito2,8, Paula Goes1,3,9. 1. Postgraduate Program of Health Science, Medical School, Federal University of Ceará, Sobral, Ceará, Brazil. 2. School of Dentistry, Federal University of Ceará. 3. Postgraduate Program of Morphological Science, Department of Morphology, Medical School, Federal University of Ceará. 4. Department of Oral and Maxillofacial Surgery and Periodontology, Ribeirao Preto School of Dentistry, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. 5. Renorbio Postgraduate Program, Federal University of Ceará. 6. Renorbio Postgraduate Program, Federal University of Pernambuco, Recife, Pernambuco, Brazil. 7. School of Medicine, Federal University of Ceará. 8. Department of Morphology, Medical School, Federal University of Ceará. 9. Department of Pathology and Legal Medicine, Medical School, Federal University of Ceará.
Abstract
BACKGROUND: Atorvastatin (ATV) has shown pleiotropic effects on bone tissue, and osteoporosis can aggravate periodontitis. Thus, the effects of ATV on experimental periodontitis (EP) in rats subjected to glucocorticoid-induced osteoporosis (GIOP) was assessed. METHODS: Male Wistar rats were divided into the following groups: 1) naive; 2) EP; 3) GIOP + EP; and 4) ATV. Groups GIOP + EP and ATV received 7 mg/kg dexamethasone intramuscularly once per week for 5 weeks, and the others received saline (SAL). Groups EP, GIOP + EP, and ATV were submitted to EP by ligature around the maxillary left second molars for 11 days. Group ATV received 27 mg/kg ATV orally, and the others received SAL 30 minutes before EP. Periodontium was analyzed by macroscopy, microtomography, and histopathology; by immunohistochemical examination of receptor activator of nuclear factor-κB ligand (RANKL), osteoprotegerin (OPG), wingless (WNT) 10b, dickkopf-related protein 1 (DKK-1), and β-catenin; and by enzyme-linked immunosorbent assay analysis of myeloperoxidase (MPO), tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-8, IL10, reduced glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT). Leukogram, liver and kidney enzymes, and bone-specific alkaline phosphatase (BALP) serum levels were evaluated. RESULTS: ATV decreased bone loss, reduced MPO, TNF-α, IL-1β, IL-6, and IL-8, and increased IL-10, GSH, SOD, and CAT levels. ATV reduced RANKL and DKK-1 and increased OPG, WNT10b, and β-catenin expressions and BALP activity. CONCLUSION: ATV reduced inflammation, oxidative stress, and bone loss in rats with EP and GIOP, with participation of the WNT signaling pathway.
BACKGROUND:Atorvastatin (ATV) has shown pleiotropic effects on bone tissue, and osteoporosis can aggravate periodontitis. Thus, the effects of ATV on experimental periodontitis (EP) in rats subjected to glucocorticoid-induced osteoporosis (GIOP) was assessed. METHODS: Male Wistar rats were divided into the following groups: 1) naive; 2) EP; 3) GIOP + EP; and 4) ATV. Groups GIOP + EP and ATV received 7 mg/kg dexamethasone intramuscularly once per week for 5 weeks, and the others received saline (SAL). Groups EP, GIOP + EP, and ATV were submitted to EP by ligature around the maxillary left second molars for 11 days. Group ATV received 27 mg/kg ATV orally, and the others received SAL 30 minutes before EP. Periodontium was analyzed by macroscopy, microtomography, and histopathology; by immunohistochemical examination of receptor activator of nuclear factor-κB ligand (RANKL), osteoprotegerin (OPG), wingless (WNT) 10b, dickkopf-related protein 1 (DKK-1), and β-catenin; and by enzyme-linked immunosorbent assay analysis of myeloperoxidase (MPO), tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, IL-8, IL10, reduced glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT). Leukogram, liver and kidney enzymes, and bone-specific alkaline phosphatase (BALP) serum levels were evaluated. RESULTS:ATV decreased bone loss, reduced MPO, TNF-α, IL-1β, IL-6, and IL-8, and increased IL-10, GSH, SOD, and CAT levels. ATV reduced RANKL and DKK-1 and increased OPG, WNT10b, and β-catenin expressions and BALP activity. CONCLUSION:ATV reduced inflammation, oxidative stress, and bone loss in rats with EP and GIOP, with participation of the WNT signaling pathway.
Entities:
Keywords:
Bone resorption; inflammation; osteoporosis; periodontitis
Authors: Mariana Dos Reis Lima; Amanda P Lopes; Conceição Martins; Gerly A C Brito; Virgínia C Carneiro; Paula Goes Journal: Front Physiol Date: 2017-06-28 Impact factor: 4.566
Authors: Paula Goes; Caio Dutra; Lennart Lösser; Lorenz C Hofbauer; Martina Rauner; Sylvia Thiele Journal: Front Immunol Date: 2019-12-10 Impact factor: 7.561